Last reviewed · How we verify
Digenin (KAINIC ACID)
Digenin (generic name: KAINIC ACID) is a drug. It is currently in Phase 2 development.
Kainic Acid activates the Glutamate receptor ionotropic, kainate 4, leading to excitotoxicity and neuronal damage.
Digenin, also known as Kainic Acid, is a small molecule modality targeting the Glutamate receptor ionotropic, kainate 4. Its mechanism of action involves activating this receptor subtype, leading to excitotoxicity and neuronal damage. However, its exact clinical use and commercial status are unclear. As a result, there is limited information available on its approved indications, half-life, bioavailability, and generic manufacturers. Further research is needed to fully understand its pharmacological properties and potential therapeutic applications.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | KAINIC ACID |
|---|---|
| Target | Adenosine receptor A3, Glutamate receptor 1, Glutamate receptor 2 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | Phase 2 |
Mechanism of action
Imagine your brain cells have special locks on them. Kainic Acid is a key that fits into one of these locks, causing the cell to become overactive and eventually die. This can be useful in research settings, but it's not a treatment for any specific medical condition.
Approved indications
Common side effects
Key clinical trials
- AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy (PHASE1,PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Digenin CI brief — competitive landscape report
- Digenin updates RSS · CI watch RSS
Frequently asked questions about Digenin
What is Digenin?
How does Digenin work?
What is the generic name of Digenin?
What development phase is Digenin in?
What does Digenin target?
Related
- Target: All drugs targeting Adenosine receptor A3, Glutamate receptor 1, Glutamate receptor 2
- Therapeutic area: All drugs in Neuroscience
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing